Bristol-Myers Squibb Company (NYSE: BMY) today announced a new agreement to expand access to Reyataz� (atazanavir sulfate). The immunity-from-suit agreement signed with Matrix Laboratories Limited, a Mylan Company, enables the generic company to manufacture and sell atazanavir, as well as stavudine and didanosine, in sub-Saharan Africa and India...
No comments:
Post a Comment